Order Article Reprints

Castañeda-Estévez E, Vergara-Dangond C, Steiner M, Paredes-Romero MB, Esteban-Vázquez A, Cobo-Ibañez T, Trives-Folguera L, Romero-Bogado ML, De La Cámara-Fernández I, Richi-Alberti P, et al. Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors. Pharmaceuticals. 2025; 18(1):22. https://doi.org/10.3390/ph18010022

Castañeda-Estévez, Elisabet, Cristina Vergara-Dangond, Martina Steiner, Maria Beatriz Paredes-Romero, Ana Esteban-Vázquez, Tatiana Cobo-Ibañez, Laura Trives-Folguera, Maria Liz Romero-Bogado, Isabel De La Cámara-Fernández, Patricia Richi-Alberti, and et al. 2025. "Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors" Pharmaceuticals 18, no. 1: 22. https://doi.org/10.3390/ph18010022

Castañeda-Estévez, E., Vergara-Dangond, C., Steiner, M., Paredes-Romero, M. B., Esteban-Vázquez, A., Cobo-Ibañez, T., Trives-Folguera, L., Romero-Bogado, M. L., De La Cámara-Fernández, I., Richi-Alberti, P., Acosta-Alfaro, A., De la Osa-Subtil, I., & Muñoz-Fernández, S. (2025). Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors. Pharmaceuticals, 18(1), 22. https://doi.org/10.3390/ph18010022